Studies Show Extremely Positive Impact on Both Men and Women SAN JOSE, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC:EROX) (BULLETIN BOARD: EROX) ("HPS" or "the Company") announced that it has filed a Comprehensive Patent Application with the U.S. Patent and Trademark Office for the use of an innovative and previously undeveloped compound with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships, personal well-being and social attraction. "We are very excited about the potential of this naturally-occurring compound that we have labeled ER 303. Just inhaling very small quantities resulted in enhanced feelings of confidence, relaxation, affection, warmth, satisfaction and sensuality, in both men and women," a spokesperson indicated. Before the Company perfected the reproduction of this compound, it could only be found in coral reefs off the coasts of Newfoundland and in the waters off Brazil's Guiabinha Island. "The Patent Application covers use in a wide range of products that may be enhanced and differentiated by the addition of ER 303, including those in the cosmetics and fragrance, personal care, environmental and household fields. Before filing for patent protection, the Company and its scientists have worked for more than eight years from the initial identification, reproducing the compound in the laboratory, conducting psychological and physiological scientific studies with men and women volunteers, and developing a manufacturing process for broad-scale production," the spokesperson also noted. The Company indicated that it is in the process of establishing http://www.er303.com/ as its website which will contain additional information about the ER 303 technology and its potential applications for consumer product companies. The Company has previously been granted broad-based worldwide patents for its initial compound, Androstadienone, which has been licensed to leading marketers, including Johnson & Johnson, Avon and Schwarkopf and Henkel and its affiliates. An HPS spokesperson indicated that the Company believes that this new compound should be of interest to the major consumer products companies around the world. This news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2007, and Form 10-Q for the nine months ended September 30, 2008 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements. DATASOURCE: Human Pheromone Sciences, Inc. CONTACT: William P. Horgan, Chairman, CEO of Human Pheromone Sciences, Inc., +1-408-938-3030 Web site: http://www.erox.com/

Copyright